Name: #S0606: Precision Medicine into Action: The Case of a Histology Independent Label - What Implications for Value Assessment?
Start: 2019-02-07T10:45:00+0100
End: 2019-02-07T11:45:00+0100

Back To Schedule

#S0606: Precision Medicine into Action: The Case of a Histology Independent Label - What Implications for Value Assessment?

Component Type: Session

A histology-independent label (encompassing all tumours with a common biomarker, regardless of tumour type) will cover an extremely heterogeneous population with varied comparators and prognoses, and likely be based on evidence from non comparative basket trials, with little or no data on survival outcomes. Representatives from health technology assessment (HTA) bodies, industry and patient organisations will discuss the challenges this poses for the value assessment of these drugs, and explore possible solutions to facilitate timely access to potentially innovative treatments for patients with no alternative options.

Chair

Sophie Cooper

Speaker

Panel Discussion
Linda Landells, PhD

Panel Discussion
Iain Leslie

Panel Discussion
Bettina Ryll

Panel Discussion
Anja Schiel, PhD

Panel Discussion
Stephen Palmer

Speakers

Sophie Cooper

Scientific Adviser, National Institute for Health and Care Excellence (NICE)

Sophie Cooper is currently a Scientific Adviser in the Science Policy and Research programme at NICE, following several years’ experience in NICE's Technology Appraisals programme. Her role involves developing Institute responses to science policy issues and undertaking and commissioning... Read More →

Linda Landells

Associate Director Technology Appraisals (Cancer Drugs Fund), National Institute for Health and Care Excellence (NICE)

Iain Leslie

Health Outcomes Manager, Communications, Policy and Access Directorate, F. Hoffmann-La Roche

Stephen Palmer

Professor, University of York

Bettina Ryll

Chair ESMO Patient Advocates Working Group (PAWG), Melanoma Patients

Bettina Ryll, MD/PhD founded the Melanoma Patient Network Europe in 2013 and developed a special interest in patient-centric clinical research and drug development. Bettina’s current areas of focus are Adaptive Licensing/ MAPPS , innovative sustainable healthcare models and patient-centered... Read More →

Anja Schiel

Special Advisor, Lead Methodologist; Leader international HTA (iHTA) NoMA, Norwegian Medicines Agency (NoMA), Norway

Anja Schiel has studied Biology at the Johannes Gutenberg-University, Mainz, Germany. She received her PhD from the Free University in Amsterdam in 2006 and worked several years as Post-Doc before starting at the Norwegian Medicines Agency (NoMA) in 2012. At NoMA she is working as... Read More →

Thursday February 7, 2019 10:45 - 11:45 CET
DIAlogue Space Austria Center Vienna Bruno-Kreisky-Platz 1 1220 Vienna Austria

06 Access to Medicines, Session

Featured Topics Value and Access
Tags Session

DIA Europe 2019